NASDAQ:HOLX - Hologic Stock Price, Price Target & More

Hologic trades on the NASDAQ under the ticker symbol "HOLX."

Hologic, Inc. (NASDAQ:HOLX) released its quarterly earnings data on Wednesday, May, 2nd. The medical equipment provider reported $0.53 earnings per share for the quarter, hitting the Zacks' consensus estimate of $0.53. The medical equipment provider earned $789.30 million during the quarter, compared to analyst estimates of $781.23 million. Hologic had a negative net margin of 4.15% and a positive return on equity of 20.86%. The firm's revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.50 earnings per share. View Hologic's Earnings History.

Hologic updated its FY18 earnings guidance on Wednesday, May, 2nd. The company provided EPS guidance of $2.22-2.27 for the period, compared to the Thomson Reuters consensus estimate of $2.26. The company issued revenue guidance of $3.18-3.21 billion, compared to the consensus revenue estimate of $3.25 billion.Hologic also updated its Q3 guidance to $0.55-0.57 EPS.

14 brokers have issued twelve-month price objectives for Hologic's shares. Their predictions range from $39.00 to $52.00. On average, they anticipate Hologic's share price to reach $45.00 in the next year. This suggests a possible upside of 8.9% from the stock's current price. View Analyst Ratings for Hologic.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hologic in the last year. There are currently 5 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Hologic saw a decrease in short interest in June. As of June 15th, there was short interest totalling 8,793,455 shares, a decrease of 19.1% from the May 31st total of 10,875,616 shares. Based on an average daily volume of 2,507,848 shares, the short-interest ratio is presently 3.5 days. Currently, 3.2% of the shares of the company are sold short. View Hologic's Current Options Chain.

Some companies that are related to Hologic include FRESENIUS SE &/S (FSNUY), Illumina (ILMN), Express Scripts (ESRX), Humana (HUM), Zoetis (ZTS), BEXIMCO PHARMAC/S GDR REGS (BXP), Baxter International (BAX), Regeneron Pharmaceuticals (REGN), HCA Healthcare (HCA), Takeda Pharmaceutical (TKPYY), ASTELLAS PHARMA/ADR (ALPMY), ESSILOR Intl S/S (ESLOY), Edwards Lifesciences (EW), Fresenius Medical Care AG & Co. (FMS) and Alexion Pharmaceuticals (ALXN).

News headlines about HOLX stock have been trending somewhat positive on Thursday, Accern Sentiment Analysis reports. The research group identifies positive and negative news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Hologic earned a coverage optimism score of 0.04 on Accern's scale. They also gave media coverage about the medical equipment provider an impact score of 48.56 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

Hologic's stock is owned by a number of of retail and institutional investors. Top institutional investors include American Capital Management Inc. (0.43%), Davis R M Inc. (0.27%), Gateway Investment Advisers LLC (0.14%), Bank of Montreal Can (0.10%), Retirement Systems of Alabama (0.05%) and Thompson Investment Management Inc. (0.03%). Company insiders that own Hologic stock include Allison P Bebo, Charles J Dockendorff, Elaine Ullian, Karleen Marie Oberton, Lawrence M Levy, Namal Nawana, Nancy Leaming, Peter J Valenti III and Sally Crawford. View Institutional Ownership Trends for Hologic.

HOLX stock was sold by a variety of institutional investors in the last quarter, including Davis R M Inc., Municipal Employees Retirement System of Michigan, Hartford Investment Management Co., Central Bank & Trust Co., Jackson Financial Management, Retirement Systems of Alabama, Amalgamated Bank and Webster Bank N. A.. Company insiders that have sold Hologic company stock in the last year include Allison P Bebo, Elaine Ullian, Karleen Marie Oberton, Lawrence M Levy and Peter J Valenti III. View Insider Buying and Selling for Hologic.

HOLX stock was bought by a variety of institutional investors in the last quarter, including Gateway Investment Advisers LLC, Bank of Montreal Can, Nisa Investment Advisors LLC, Reilly Financial Advisors LLC, DnB Asset Management AS, Curbstone Financial Management Corp, Eastern Bank and Ledyard National Bank. Company insiders that have bought Hologic stock in the last two years include Charles J Dockendorff and Namal Nawana. View Insider Buying and Selling for Hologic.

Shares of HOLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of HOLX stock can currently be purchased for approximately $41.32.

Hologic has a market capitalization of $11.33 billion and generates $3.06 billion in revenue each year. The medical equipment provider earns $755.50 million in net income (profit) each year or $2.03 on an earnings per share basis. Hologic employs 6,233 workers across the globe.

Hologic's mailing address is 250 CAMPUS DRIVE, MARLBOROUGH MA, 01752. The medical equipment provider can be reached via phone at 508-263-2900 or via email at [email protected]